BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, December 27, 2025
Home
»
Newsletters
» BioWorld Science
BioWorld Science
May 6, 2021
View Archived Issues
Triumvira initiates phase I/II trial of TAC-01-HER2 in relapsed or refractory solid tumors
Read More
First-in-human trial evaluates RPTR-168 in HPV-16 E6/E7-positive tumors and melanoma
Read More
AbCellera and Eli Lilly present second antibody to enter clinical development against COVID-19
Read More
First-in-human data for RZ-402 show potential for once-daily dosing
Read More
Vivace advances phase I trial of VT-3989 in solid tumors
Read More
Seqirus quadrivalent influenza vaccine Flucelvax noninferior to standard in children
Read More
Oral oncolytic reovirus RC-402 elicits potent immune responses against colon cancer
Read More
Novel GLUT5 inhibitor molecule to treat fructose-induced diseases
Read More
Study identifies four Alzheimer's subtypes
Read More
Silverback Therapeutics patents TGFBR1 inhibitors
Read More
Boswellic acid derivative inhibits Th17 cell differentiation by targeting eIF2alpha
Read More
Combination of pacritinib/sirolimus/low-dose tacrolimus for GvHD: preclinical and phase I results
Read More
Pipeline Therapeutics synthesizes muscarinic M1 receptor antagonists
Read More
BioCryst Pharmaceuticals patent details complement factor D inhibitors
Read More
Boehringer Ingelheim discovers TRPA1 antagonists
Read More
General Regeneratives patents IL-33 protein for cancer immunotherapy
Read More
FDA grants accelerated approval to Keytruda for first-line gastric or GEJ adenocarcinoma
Read More
Adagio initiates global phase II/III EVADE study of ADG-20 for the prevention of COVID-19
Read More
GB-1265: a galactin-3 inhibitor for corneal fibrosis
Read More
Revelation reports phase I data on REVTx-99
Read More
ADG-126, a novel cancer immunotherapy candidate with improved safety and efficacy
Read More
European Commission approves Xtandi for metastatic hormone-sensitive prostate cancer
Read More
Benlysta approved in E.U. for active lupus nephritis
Read More
Targeting RRM2 and mutant p53 as novel therapeutic strategy in TNBC
Read More
Moderna reports initial COVID-19 vaccine booster data with mRNA-1273 and mRNA-1273.351
Read More
Phase II trial evaluates Telomelysin, pembrolizumab and stereotactic radiation in head & neck cancer
Read More